Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

GnRH-a will be used to postpone period after vaginal repair for Cesarean Section Scar Defect(CSD) patients with adenomyosis which will be compared with CSD patients with adenomyosis who receive transvaginal surgery without GnRH-a, whether delayed period improving the CSD prognosis will be assessed.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:

• Clearly diagnosed with CSD complicated with adenomyosis

• Experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 10 days).

• The thickness of the remaining muscular layer of CSD was less than 3 mm.

• Normal range of blood sugar and insulin

• No serious medical problems (important viscera function in the normal range).

• uterine fibroids no more than 5cm

• Sign the informed consent.

Locations
Other Locations
China
Shanghai Jiaotong University xinhua hospital
RECRUITING
Shanghai
Contact Information
Primary
Wang Xipeng
steveoizzie@icloud.com
+862125078999
Time Frame
Start Date: 2023-05-01
Estimated Completion Date: 2026-04-30
Participants
Target number of participants: 94
Treatments
Experimental: Vaginal Repair with Leuprorelin
CSD patients were treated with vaginal repair of CSD in combination with Leuprorelin . In the group of Vaginal Repair With Leuprorelin, the patients will get 3 times of Leuprorelin per 4 weeks perioperation. The detailed procedure of Vaginal Repair has been described in our previous study.
No_intervention: Vaginal Repair without Leuprorelin
The detailed procedure of Vaginal Repair has been described in our previous study.
Related Therapeutic Areas
Sponsors
Leads: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

This content was sourced from clinicaltrials.gov